Donald Trump's re-election in 2024 may impact biopharmaceutical M&A activity due to potential changes in FTC leadership and policies. His 'America First' stance and healthcare policy uncertainties could affect the industry's future growth and innovation.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing